Naurif

• Chemotherapy-induced nausea and vomiting - initial and repeat courses
• Radiation-induced nausea and vomiting - total body irradiation and fractionated abdominal radiation
• Postoperative nausea and vomiting - prevention and treatment

Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center and through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.

Injection (Chemotherapy):

• Adults: 10 mcg/kg IV (30 minutes before chemotherapy)
• Children (2-16 years): 10 mcg/kg IV

Injection (Postoperative):

• Prevention: 1 mg IV (before anesthesia induction)
• Treatment: 1 mg IV (over 30 seconds)

Tablet (Chemotherapy):

• 2 mg once daily or 1 mg twice daily

Tablet (Radiation):

• 2 mg once daily (1 hour before radiation)

Elderly, Renal/Hepatic: No dosage adjustment required

* Use as directed by the registered physician

Common Side Effects:

• Headache
• Constipation
• Diarrhea
• Weakness
• Sleepiness
• Dizziness
• Abdominal pain
• Dyspepsia
• Anxiety
• Insomnia

Use in Pregnancy: Generally considered safe during pregnancy. Animal studies have shown low or no adverse effects.

Precautions:

• Caution in patients with cardiac comorbidities, cardiotoxic chemotherapy and electrolyte abnormalities
• May mask progressive ileus and gastric distention
• Caution in pregnancy and lactation
• Be cautious while driving (may cause drowsiness)

Overdose: Overdose may cause headache, nausea, diarrhea. Symptomatic and supportive treatment should be given.

Storage: Injection: Store below 25°C. Protect from light. Tablet: Protect from light.